Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

June 27, 2006; 66 (12) Patient Page

Chronic migraine and medication-overuse headache

Eric J. Eross
First published June 26, 2006, DOI: https://doi.org/10.1212/01.wnl.0000227588.24559.89
Eric J. Eross
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Chronic migraine and medication-overuse headache
Eric J. Eross
Neurology Jun 2006, 66 (12) E43-E44; DOI: 10.1212/01.wnl.0000227588.24559.89

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
3808

Share

  • Article
  • Info & Disclosures
Loading

Many medications that people take for migraine headaches can actually make headaches worse, if the medications are taken too frequently. When this occurs, the resulting problem is called “medication-overuse headaches.” Unfortunately, when medication-overuse headaches occur, they can be difficult to treat. You can read more about migraine headaches and medication-overuse headaches on the next page.

How can medication-overuse headaches be treated?

In this issue of Neurology, Zeeberg and colleagues1 looked at the effect of a 2-month drug-free period in patients suffering from probable medication-overuse headache. They closely followed 337 patients seen at the Danish Headache Center with medication-overuse headache. The goal was to see the effects on headache frequency solely by eliminating the suspected culprit acute medication. Of the 337 patients who had their medications abruptly withdrawn, 64% (216 patients) were able to stay medication-free for 2 months. The researchers found that overall, 45% of the patients had improved in 2 months, 48% had no change, and only 7% had more headaches.

Does the original headache type leading to probable medication-overuse headache determine response to acute medication withdrawal?

Of the 216 patients with medication-overuse headache, the original headache types leading to overtreatment included migraine (10%), tension-type headache (33%), both migraine and tension-type headache (43%), and other (14%). Importantly, a previous diagnosis of migraine appeared to predict a better response to medication withdrawal. Patients with migraine only initially enjoyed a 67% reduction in headache frequency. This was dramatically different than those individuals who initially had tension-type headache only or another type of headache; these patients had absolutely no reduction of headache frequency 2 months after medication withdrawal. Patients who had both tension-type headache and migraine had a 37% reduction in overall headache frequency.

Does it matter which medications were the potential culprits in probable medication-overuse headache?

Of the 216 patients, 4% were overusing ergots, 6% narcotics, 20% triptans, 29% simple analgesics (pain relievers), and 42% combination analgesics (multiple pain relievers in one tablet). The ergots and triptan drugs are considered “acute” treatments for headache because when they are effective, they shut down the headache quickly. Narcotics and analgesics are given to simply relieve the headache pain. The researchers found that the response to medication withdrawal also depended on the medication being overused. For example, patients overusing ergots and triptans showed the most improvement whereas patients taking narcotics and analgesics were less likely to respond (only one in three improved).

What is the takeaway message from the Danish study?

Even if no other therapies are begun, eliminating pain and other acute medications is often an effective treatment in cases of probable medication-overuse headache. In particular, migraineurs and patients overusing ergots and triptans may benefit the most. Most experts agree that eliminating potential culprit medications is the cornerstone of successful treatment. Often, clinicians will use other “tricks of the trade” to improve a patient’s odds for success such as starting a drug designed to prevent headaches (known as a prophylactic agent). Usually patients will also be supplied with alternative acute agents thought to be less likely to perpetuate the headache cycle.

The most important thing to remember is that while pain and other acute medications can be extremely effective for treating the occasional migraine headache, using them more than twice a week can actually lead to a problem that can be worse than the migraine headache itself.

What is migraine and how common is it?

Migraine headache is a common medical condition that afflicts an estimated 28 million Americans, nearly as many who suffer from asthma, diabetes, and osteoarthritis combined. Over 80% of these migraineurs (patients suffering from migraine) state that they experience either severe or extremely severe pain during their attacks, and over half experience severe headache-related disability. Not uncommonly the pain is on one side of the head, takes on a throbbing quality, and is made worse with routine physical activity such as going up stairs or bending over. Patients often experience nausea (with or without vomiting) as well as sensitivity to light (photophobia) and sound (phonophobia).

What causes migraine to increase in frequency?

With regard to headache frequency, experts generally divide migraine into either an episodic or chronic condition (headache occurring greater than 15 days per month for longer than 3 months). Risk factors for progressing from an episodic pattern to a chronic pattern include such things as education/socioeconomic status, obesity, baseline attack frequency, sleep apnea (airway obstruction during sleep), stressful life events, caffeine consumption, and notably the overuse of medications designed to get rid of an existing headache (known as an “acute” or “abortive” drug). These medications are also known as “symptomatic medications.” Of these risk factors, experts believe that limiting a patient’s exposure to acute drugs may be one of the most effective ways to prevent the progression to chronic daily headache.

What is medication-overuse headache and what causes it?

Medication-overuse headache, previously know as “rebound headache,” is a condition in which headaches become more and more frequent as a patient begins to use more and more acute headache medications. It’s a downward spiral in the truest sense; the more medications you use, the more headaches you get, thus the inclination to use more of the culprit medication, and so on. Researchers are unsure as to what causes medication-overuse headache, but most agree that migraineurs are particularly susceptible to this phenomenon.

Which medications cause medication-overuse headache and how much is too much?

Almost all symptomatic medications have the potential to cause medication-overuse headache if used too frequently. Having said that, experts believe that some medications have a higher potential than others. Studies suggest that butalbital-containing drugs (i.e., Fiorinal and Fioricet), narcotics, acetaminophen (Tylenol), ergot compounds (e.g., Cafergot), nonsteroidal anti-inflammatory drugs (NSAIDs), and the migraine-specific drugs known as the triptans may be the most common culprits. Dihydroergotamine (Migranal Nasal Spray), antiemetics (used for both headache and nausea), COX-2 inhibitors (e.g., Celebrex), and straightforward aspirin are thought to have a very low risk. Generally speaking, experts advise patients to avoid taking symptomatic medications more than two days per week. We do not know how long it takes to develop this condition, but some suggest it can occur within a few short months.

What should I do if I think I might have medication-overuse headache?

If you are taking one of the medications listed above, or any other pain medication more than twice a week for headache, you are at risk for developing medication-overuse headache. If you think you have developed medication-overuse headache, you should talk to your doctor about other options for treating your headache problem. If your headaches have become severe enough that you feel you need pain medication more than twice a week, you should also talk with your doctor about the best treatment strategy for you. Trying to treat the problem on your own, even with frequent use of over-the-counter pain medications, could actually make the problem worse and lead to medication-overuse headache.

For more information

The National Headache Foundation www.headaches.org

American Academy of Neurology Foundation www.thebrainmatters.org

Reference

  1. 1.↵
    Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology 2006;66:1894–1898.
    OpenUrlAbstract/FREE Full Text
View Abstract

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Reference
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise